Advances in Heart Failure Pharmacotherapy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".
Deadline for manuscript submissions: 31 July 2026 | Viewed by 27
Special Issue Editor
Special Issue Information
Dear Colleagues,
Heart failure is the final common pathway for many cardiovascular risk factors and diseases. It is a complex clinical syndrome caused by structural or functional abnormalities that impair ventricular filling or ejection, in turn leading to an inability to meet metabolic demands. Despite advances in care, heart failure remains associated with high morbidity and mortality. An estimated 26 million people live with chronic heart failure worldwide, with substantial healthcare costs and marked reduction in quality of life. Guideline-directed medical therapy emphasizes the modulation of overactive neurohormonal pathways, using a quadruple regimen that includes β-blockers, renin angiotensin aldosterone system inhibitors or angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium glucose cotransporter 2 inhibitors. Treatment response varies widely between individuals, and the optimal regimen for a given patient may differ based on individual factors, such as sex, disease phenotype, complications, and co-morbidities.
This Special Issue focuses on advancing pharmacotherapy for heart failure, including studies focusing on personalized medicine. We welcome clinical and pre-clinical mechanistic studies, as well as rigorous evidence syntheses, that evaluate novel therapeutic targets, combinations, and treatment algorithms. Submissions that address variations in pharmacokinetics and pharmacodynamics, sequencing or dosing protocols, biomarker or genotype-guided care, and drug combinations that reduce adverse clinical outcomes while providing mechanistic insight are also encouraged.
Dr. Persoulla A. Nicolaou
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- heart failure
- pharmacotherapy
- precision medicine
- pharmacogenomics
- pharmacokinetics
- pharmacodynamics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
